None listed
Conditions
Interventions
Oral intake of the test product (1 capsule 3 times in a day
8 weeks).
Oral intake of the placebo product (1 capsule 3 times in a day
8 weeks).
Sponsors
TES Holdings Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Healthy Japanese females aged 30-59 years. [2] Individuals who are healthy and have no chronic physical disease including skin disease. [3] Individuals who are aware of skin dryness and sagging. [4] Individuals whose written informed consent has been obtained after explanation of this study. [5] Individuals who can have an examination on a designated check day [6]Individuals judged appropriate for the study by the principal.
Exclusion criteria
Exclusion criteria: [1] Individuals using medical products. [2] Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [3] Individuals with strange skin conditions at measurement points. [4] Individuals with strange skin conditions at measurement points. [5] Individuals who used a drug to treat a disease in the past 1 month. [6] Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease. [7] Individuals who contract or have a history of serious gastrointestinal disease. [8] Individuals with serious anemia. [9] Individuals whose BMI is over 30 kg/m2. [10] Individuals who are sensitive to the test food. [11] Individuals who have a habit to use drug claiming to improve skin condition in the past 3 months. [12] Individuals who have a habit to ingest health-promoting foods, or supplements containing similar composition with a test food in the past 3 months or will ingest those foods during the test period. [13] Individuals who have, within the last 3 months have had or will have a habit of ingesting health supplements containing NMN during the test period. [14] Individuals who excessively take alcohol (expressed in an amount of alcohol: over 30mg/day). [15] Individuals with possible changes of life style during the test period. [16] Individuals who will develop seasonal allergy symptoms like hay fever and be to suffer from worsening eyes and nose symptoms or use anti-allergic drugs during the test period. [17] Individuals who will get sunburned during the test period. [18] Individuals who had been conducted an operation or beauty treatment on the test spot. [19] Individuals who are or are possibly pregnant, or are lactating. [20] Individuals who participated in other clinical studies in the past 3 months. [21] Individuals who are or whose family is engaged in health foods of functional foods. [22] Individuals judged inappropriate for the study by the principal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Indexes for skin function. [1]Transepidermal water loss(Week 0, Week 8). [2]Skin moisture content(Week 0, Week 8). [3]Skin viscoelasticity(Week 0, Week 8). | — |
Secondary
| Measure | Time frame |
|---|---|
| *Secondary indexes [1] Observation for skin condition by dermatologists (Week 0, Week 8). [2] Anti-Aging QOL Common Questionnaire (Week 0, Week 8). [3] Visual Analogue Scale (Week 0, Week 8). [4] Specific blood test (Week 0, Week 8). *Safety [1] Blood pressure, pulsation (Week 0, Week 8). [2] Weight, body fat percentage, BMI (Week 0, Week 8). [3] Blood test (Week 0, Week 8). [4] Blood biochemical test (Week 0, Week 8). [5] Urine analysis (Week 0, Week 8). [6] Doctor's questions (Week 0, Week 8). [7] Adverse events: number of cases and expression rate of adverse events (Week 8). [8] Subject's diary (From the first day of ingestion of a test material to the last day of the test). | — |
Countries
Japan
Contacts
Public ContactRyoma Shimizu
TES Holdings Co., Ltd. Administrative Department of Clinical Trials
Outcome results
None listed